Flux · Translational psychiatry 2023 · randomized controlled trial · n=30

Association of plasma cytokines and antidepressant response following mild-intensity whole-body hyperthermia in major depressive disorder.

Cited 16 times in the scientific literature.

Level 2 - randomized trial

Individual randomized controlled trial

PubMed 37085494 · doi:10.1038/s41398-023-02402-9 · record verified 2026-08-30

What was done

Thirty participants meeting DSM-IV-TR criteria for major depressive disorder were randomized to receive a single session of whole-body hyperthermia (WBH, n = 16) or a sham treatment (n = 14). Hamilton Depression Rating Scale (HDRS) scores were measured at baseline and at 1, 2, 4, and 6 weeks post-treatment. Plasma cytokine concentrations were assessed at baseline, immediately post-treatment, and at 1 and 4 weeks post-treatment.

What was found

Compared to sham, WBH significantly increased plasma interleukin-6 (IL-6) immediately post-treatment (time by treatment: χ2(3, N=108) = 47.33, p < 0.001), with no acute effect on other cytokines and no significant differences in IL-6 or other cytokines at 1 or 4 weeks post-treatment. Across the full sample, higher post-treatment IL-6 levels were associated with lower HDRS depression scores over the 6 weeks of follow-up (F(1, 102.3) = 6.74, p = 0.01).

Why it matters

These findings indicate that the antidepressant effect of whole-body hyperthermia is linked to a transient, isolated acute surge in IL-6 rather than broad anti-inflammatory suppression.

Limits

The study is limited by a very small sample size (30 participants total across two groups). The abstract does not specify which other cytokines were measured, nor does it report patient demographics or concurrent medication use.

Cited by